Platelet-derived bio-products: Classification update, applications, concerns and new perspectives

Acebes-Huerta, Andrea; Arias-Fernández, Tamara; Bernardo, Ángel; Muñoz-Turrillas, María Carmen; Fernández-Fuertes, Judit; Seghatchian, Jerard; Gutiérrez, Laura

doi:10.1016/j.transci.2019.102716

Cited by 36 publications

(35 citation statements)

References 131 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…An intense debate for a consensus definition and classification of the plethora of PRP-related products of clinical use persists in the scientific community in the past decade (8,(56)(57)(58)(59)(60)(61)(62). From Mishra et al (63) to Kon et al (64), different classifications methods have been proposed for human PRP.…”

Section: Classification Of Platelet Concentrates In Human Regenerativmentioning

confidence: 99%

A Critical Overview of the Use of Platelet-Rich Plasma in Equine Medicine Over the Last Decade

2021

View full text Add to dashboard Cite

In the 1990s, the role of platelets in inflammation and tissue healing was finally recognized. Since then, the clinical use of platelet-derived products (hemocomponents), such as, platelet-rich plasma (PRP), markedly increased. The promise of a more economical option of a disease-modifying treatment led to the intensive and continuous research of PRP products and to its widespread clinical use. A number of protocols and commercial kits have been developed with the intention of creating a more practical and reliable option for clinical use in equine patients. Still, the direct comparison between studies is particularly challenging due to the lack of standardization on the preparation methods and product composition. The incomplete reports on PRP cellular concentration and the poorly designed in vivo studies are additional matters that contest the clinical efficiency of this biomaterial. To overcome such challenges, several in vitro and in vivo studies have been proposed. Specifically, experiments have greatly focused in protocol optimization and its effect in different tissues. Additionally, in vivo studies have proposed different biological products envisioning the upgrade of the anti-inflammatory cytokines trusting to increase its anti-inflammatory effect. The individual variability and health status of the animal, type of tissue and condition treated, and protocol implemented are known to influence on the product's cell and cytokine composition. Such variability is a main clinical concern once it can potentially influence on PRP's therapeutic effects. Thus, lack of qualitative and quantitative evidence-based data supporting PRP's clinical use persists, despite of the numerous studies intended to accomplish this purpose. This narrative review aims to critically evaluate the main research published in the past decade and how it can potentially impact the clinical use of PRP.

show abstract

Section: Classification Of Platelet Concentrates In Human Regenerativmentioning

confidence: 99%

A Critical Overview of the Use of Platelet-Rich Plasma in Equine Medicine Over the Last Decade

2021

View full text Add to dashboard Cite

show abstract

“…PLTs and artificial PLTs can be converted into drug carriers, given their ability to target and migrate to sites of injuries or disease [121][122][123]. In addition, their newly-identified functions in immune modulation, inflammation, cancer, and tissue regeneration [124][125][126] open the door to the in vitro production of fine-tuned PLTs, both at the receptor and the cargo levels, that can potentially modulate these pathological states [127][128][129].…”

Section: Artificial Platelets and Applications Beyond Transfusion Med...mentioning

confidence: 99%

On the Quest for In Vitro Platelet Production by Re-Tailoring the Concepts of Megakaryocyte Differentiation

et al. 2020

Self Cite

View full text Add to dashboard Cite

The demand of platelet transfusions is steadily growing worldwide, inter-donor variation, donor dependency, or storability/viability being the main contributing factors to the current global, donor-dependent platelet concentrate shortage concern. In vitro platelet production has been proposed as a plausible alternative to cover, at least partially, the increasing demand. However, in practice, such a logical production strategy does not lack complexity, and hence, efforts are focused internationally on developing large scale industrial methods and technologies to provide efficient, viable, and functional platelet production. This would allow obtaining not only sufficient numbers of platelets but also functional ones fit for all clinical purposes and civil scenarios. In this review, we cover the evolution around the in vitro culture and differentiation of megakaryocytes into platelets, the progress made thus far to bring the culture concept from basic research towards good manufacturing practices certified production, and subsequent clinical trial studies. However, little is known about how these in vitro products should be stored or whether any safety measure should be implemented (e.g., pathogen reduction technology), as well as their quality assessment (how to isolate platelets from the rest of the culture cells, debris, microvesicles, or what their molecular and functional profile is). Importantly, we highlight how the scientific community has overcome the old dogmas and how the new perspectives influence the future of platelet-based therapy for transfusion purposes.

show abstract

“…PRP has various growth factors, including fibroblast growth factor, epidermal growth factor, vascular endothelial growth factor, platelet-derived growth factor, transforming growth factor-β, and insulin-like growth factor [ 27 ]. Despite the focused use of PRP, the efficacy of PRP remains under debate because of the lack of consensus in the optimal preparation condition for tissue regeneration [ 28 ]. The clear effect of PRP on osteogenic differentiation remains to be elucidated and some studies have reported conflicting results about the effect of PRP on osteogenesis [ 29 , 30 ].…”

Section: Introductionmentioning

confidence: 99%

Development of Intracorporeal Differentiation of Stem Cells to Induce One-Step Mastoid Bone Reconstruction during Otitis Media Surgeries

et al. 2022

View full text Add to dashboard Cite

Mastoidectomy is a surgical procedure for the treatment of chronic otitis media. This study investigated the ability of rat stromal vascular fraction cells (rSVF) in combination with polycaprolactone (PCL) scaffolds and osteogenic differentiation-enhancing blood products to promote the regeneration of mastoid bone defect. Twenty male Sprague Dawley rats were randomly divided according to obliteration materials: (1) control, (2) PCL scaffold only, (3) rSVFs + PCL, (4) rSVFs + PCL + platelet-rich plasma, and (5) rSVFs + PCL + whole plasma (WP). At 7 months after transplantation, the rSVFs + PCL + WP group showed remarkable new bone formation in the mastoid. These results indicate that SVFs, PCL scaffolds, and blood products accelerate bone regeneration for mastoid reconstruction. Autologous SVF cells with PCL scaffolds and autologous blood products are promising composites for mastoid reconstruction which can be easily harvested after mastoidectomy. With this approach, the reconstruction of mastoid bone defects can be performed right after mastoidectomy as a one-step procedure which can offer efficiency in the clinical field.

show abstract

Platelet-derived bio-products: Classification update, applications, concerns and new perspectives

Cited by 36 publications

References 131 publications

A Critical Overview of the Use of Platelet-Rich Plasma in Equine Medicine Over the Last Decade

A Critical Overview of the Use of Platelet-Rich Plasma in Equine Medicine Over the Last Decade

On the Quest for In Vitro Platelet Production by Re-Tailoring the Concepts of Megakaryocyte Differentiation

Development of Intracorporeal Differentiation of Stem Cells to Induce One-Step Mastoid Bone Reconstruction during Otitis Media Surgeries

Contact Info

Product

Resources

About